ODC1 and neuroblastoma: However, while the polyamine synthesis inhibitor DFMO, which targets ODC1, appeared promising in reducing relapse and increasing overall survival time as maintenance therapy for high‐risk neuroblastoma in remission, it was not very effective in the relapsed setting [7, 8, 9].